Norgine B.V. said Swissmedic has granted marketing authorisation for PEDMARQSI, a sodium thiosulfate infusion, to prevent cisplatin-induced ototoxicity in paediatric patients aged 1 month to under 18 years with localised, non-metastatic solid tumours in Switzerland. The approval makes PEDMARQSI the first authorised treatment in the country specifically aimed at reducing chemotherapy-related hearing loss in this setting, with the decision supported by data from the Phase 3 SIOPEL 6 and COG ACCL0431 studies that the company said showed roughly a 50% reduction in ototoxicity versus cisplatin alone.

Why the Swissmedic approval could matter far beyond Switzerland’s small paediatric oncology market

This approval matters because it addresses one of the most durable blind spots in paediatric oncology supportive care. Cisplatin remains one of the most important chemotherapeutic agents used in childhood solid tumours, but its association with irreversible bilateral hearing loss has long created a brutal trade-off between cancer control and lifelong developmental harm. In practice, hearing damage is not a cosmetic side effect. It can alter speech development, classroom performance, psychosocial function, and long-term quality of life, which means the supportive care decision can carry consequences that extend well beyond the treatment window.

What makes this approval more important than a routine national label expansion is that it shifts hearing preservation closer to the status of an active treatment goal rather than an unfortunate risk to be monitored after the fact. In paediatric oncology, regulators and clinicians have become more sensitive to survivorship burden, especially as cure rates improve in several childhood cancers. A pharmacologic intervention that can reduce ototoxicity without evidently undermining anti-cancer efficacy changes the discussion from passive damage control to proactive prevention. That is strategically significant for developers working in supportive oncology, a category that often receives less investor and policy attention than frontline therapeutics despite its real-world impact on long-term outcomes.

What PEDMARQSI’s label reveals about where supportive oncology innovation is finally becoming more targeted

The PEDMARQSI decision also reflects a broader change in how niche supportive care products are being evaluated. For years, paediatric oncology supportive care often relied on guideline variation, local practice, and off-label workarounds rather than formally authorised products built around specific toxicity risks. PEDMARQSI stands out because it was developed specifically for a defined toxicity problem in a defined paediatric population, not repurposed into that role after the fact.

That matters commercially and clinically. Commercially, a therapy with a precise preventive claim can be easier to position with regulators, hospital formularies, and payer systems than a loosely framed adjunctive intervention. Clinically, it helps standardise expectations around timing, eligible population, and outcome measurement. It also raises the bar for future supportive care entrants. Once a product becomes the first authorised option in a country, hospitals and regulators are less likely to view prevention of treatment-related hearing loss as an optional extra. They are more likely to ask whether similar toxicity-mitigation strategies should be developed in other paediatric chemotherapy settings.

Why the Phase 3 data look meaningful but still leave clinicians with practical questions

The source material ties Swissmedic’s decision to two open-label, randomised Phase 3 trials, SIOPEL 6 and COG ACCL0431, and says the combined evidence showed an approximate 50% reduction in cisplatin-induced hearing loss versus cisplatin alone while maintaining chemotherapy efficacy. On the surface, that is clinically meaningful because ototoxicity prevention needs to be large enough to justify the added infusion burden and treatment complexity. A marginal signal would have been unlikely to shift practice. A reduction of this scale is more compelling, particularly in a paediatric population where even moderate hearing impairment can have outsized developmental consequences.

Still, trial strength does not eliminate implementation questions. Open-label randomised studies can be entirely appropriate in this type of setting, but clinicians will still focus on granularity that often determines uptake at the bedside. They are likely to watch for how hearing outcomes were assessed across centres, how consistent benefit appeared across tumour types and age groups, and whether real-world delivery proves as manageable as trial delivery. They are also likely to remain attentive to the timing of sodium thiosulfate administration relative to cisplatin, because supportive agents in oncology often succeed or fail operationally based on whether they fit routine infusion workflows without introducing treatment delays.

What Swissmedic’s decision suggests about regulatory comfort with survivorship-focused endpoints in children

Swissmedic’s authorisation is notable because it signals regulatory willingness to treat prevention of long-term toxicity as a sufficiently important endpoint in paediatric oncology when supported by controlled evidence. That may sound obvious, but regulatory systems have historically been more comfortable approving products tied to tumour response, progression metrics, or survival outcomes than therapies aimed at preserving function after cure. PEDMARQSI sits in that less glamorous but increasingly important territory where regulators are being asked to recognise that avoiding lifelong disability can be a major therapeutic achievement in its own right.

The approval also reinforces that paediatric-focused regulatory routes remain essential for specialised medicines. Norgine said PEDMARQSI had already received paediatric use marketing authorisation from the European Medicines Agency in 2023 and national approval in the United Kingdom, suggesting a sequential European regulatory strategy built around rare and specialist medicine pathways. That history does not guarantee rapid uptake everywhere, but it does reduce the perception that Switzerland is an outlier event. Instead, it places Swissmedic within a growing regional pattern of acceptance for the product.

What this approval changes for hospital adoption, treatment protocols, and reimbursement discussions

The next challenge is not proving that cisplatin hearing loss is serious. That case has already been made. The harder challenge is embedding prevention into routine care. Hospital adoption will depend on whether paediatric oncology centres view PEDMARQSI as practical enough to integrate into established cisplatin protocols and whether reimbursement systems accept that the up-front cost of preventive treatment is justified by the avoided long-term burden of hearing impairment.

This is where supportive oncology products often run into friction. The long-term value proposition can be strong, but the budget impact appears immediately while the developmental and educational benefits accrue over years. That disconnect can slow adoption even after approval. In Switzerland, where the product now has formal regulatory backing, the authorisation should make those discussions easier, but not automatic. Pharmacy and therapeutics committees will still want clarity on eligible populations, workflow demands, and the consistency of benefit across real-world settings.

Manufacturing and supply also matter more than they may appear. A niche paediatric oncology product does not need blockbuster volume, but it does need reliable availability, especially if clinicians start to treat ototoxicity prevention as standard rather than discretionary. Any interruption in supply could quickly weaken confidence at the hospital level, because clinicians are unlikely to redesign pathways around a product they are not sure they can obtain consistently.

Why PEDMARQSI’s Swiss milestone strengthens Norgine’s position in rare and specialist medicines but does not remove execution risk

For Norgine B.V., the approval strengthens its strategic profile as a regional specialty pharmaceutical player capable of commercialising targeted products in under-served therapeutic niches. The product is not just another oncology asset. It sits at the intersection of paediatrics, supportive care, survivorship, and rare disease-style commercial execution. Those are categories where smaller and mid-sized specialty firms can build durable value if they navigate regulatory fragmentation and hospital adoption well enough.

But the execution risk remains very real. The Swiss decision validates the regulatory case, not the full commercial one. Supportive care products can struggle when prescribers remain conservative, when treatment pathways vary significantly between centres, or when budget holders do not fully credit long-term quality-of-life gains. The fact that PEDMARQSI is first in class in Switzerland is an advantage, but it also means the market must still be educated. First approvals in niche categories often come with the burden of creating the treatment habit from scratch.

What clinicians, regulators, and industry observers are likely to watch after this Swissmedic approval

The next phase of scrutiny will likely centre on whether the Swiss authorisation translates into broader protocol inclusion and whether additional real-world evidence reinforces confidence in both effectiveness and tolerability. Norgine said the most commonly reported adverse events included nausea and vomiting, while infection, anaemia, and neutropenia were the most common grade 3 to 4 events reported in the trials. Even when those findings are manageable, clinicians will want to see how the benefit-risk profile feels in actual hospital use rather than only in controlled study settings.

Industry observers will also watch whether PEDMARQSI remains a niche supportive care success or becomes a signal that paediatric oncology is finally ready to reward therapies designed around survivorship preservation. If uptake proves meaningful, the Swiss decision may end up representing more than a local regulatory event. It could become evidence that paediatric supportive oncology is emerging as a more investable and strategically serious segment, especially where the burden of treatment-related harm is permanent, measurable, and increasingly difficult for health systems to ignore.

  cisplatin-induced ototoxicity, hearing loss prevention, Norgine, paediatric oncology, PEDMARQSI, SIOPEL 6, sodium thiosulfate, solid tumours, supportive oncology, Swissmedic